Adherence to statin therapy in patients with high and very high cardiovascular risk in real clinical practice

Despite the proven efficacy of lipid-lowering therapy, adherence to long-term statin therapy in patients with cardiovascular disease remains low.

Aim. To study adherence to long-term statin therapy and factors associated with adherence in patients with high and very high cardiovascular risk (CVR) in real clinical practice.

Materials and methods. The single-center cohort study included 53 patients (mean age 68.1 ± 10.2 years) with high or very high CVR on the SCORE scale and have been taking statins for at least 3 months prior to inclusion in the study. The level of low-density lipoprotein cholesterol (LDL-C), cognitive impairment (MoCA test), anxiety and depression (HADS scale), presence of senile asthenia (FRAIL scale), M. Charlson comorbidity index were assessed. Adherence to statin therapy was assessed using the original questionnaire. The correlation between patient adherence and ordinal variables for the scores of the studied scales was studied.

Results. Completely adherent to statin therapy were only 12 (22%) patients, 14 (26%) were insufficiently adherent, 27 (51%) were non-adherent. The target level of LDL-С was achieved in 13 (25%) patients. 38 (72%) patients showed a decrease in cognitive functions; a positive correlation was found between adherence and the MoCA test (r = 0.44, p = 0.04). Clinical and subclinical depression and anxiety were noted in 12 (23%) and 14 (26%) patients, respectively. A statistically significant negative correlation was found between adherence and depression (r = –0.32; p = 0.04) and a positive correlation between adherence and anxiety (r = 0.44; p = 0.04). There was no statistically significant correlation between adherence and the FRAIL fragility scale, as well as the M. Charlson comorbidity index.

Conclusions. Depression and cognitive decline are associated with decreased adherence to statin therapy.

1. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349–57. https://doi.org/10.1056/NEJM199811053391902 PMID: 9841303

2. Сергиенко И.В., Аншелес А.А., Драпкина О.М. и др. Исследование АНИЧКОВ: влияние комбинированной гипотензивной и гиполипидемической терапии на сердечно-сосудистые осложнения у пациентов высокого и очень высокого риска. Терапевтический архив. 2019; 91(4): 90–8. https://doi.org/10.26442/00403660.2019.04.000104

3. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003; 361: 1149–58. https://doi.org/10.1016/S01406736(03)12948-0 PMID: 12686036

4. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5

5. Mann D.M., Woodward M., Munther P., et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010; 44(9): 1410–21. https://doi.org/10.1345/aph.1P150 PMID: 20702755

6. Пучиньян Н.Ф., Довгалевский Я.П., Долотовская П.В., Фурман Н.В. Приверженность рекомендованной терапии больных, перенесших острый коронарный синдром, и риск развития сердечно-сосудистых осложнений в течение года после госпитализации. Рациональная Фармакотерапия в Кардиологии. 2011; 7(5): 567–73. https://doi.org/10.20996/1819-6446-2011-7-5-567-573

7. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288: 462–7. https://doi.org/10.1001/jama.288.4.462 PMID: 12132976

8. Lemstra M., Blackburn D., Crawley A., Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012; 28(5): 574–80. https://doi.org/10.1016/j.cjca.2012.05.007 PMID: 22884278

9. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987–1003. https://doi.org/10.1016/s0195-668x(03)00114-3 PMID: 12788299

10. Mach F., Baigent C., Catapano A., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardio vascular risk. European Heart Journal. 2020; 41(1): 111–88. https://doi.org/10.1093/eurheartj/ehz455

11. Charlson M., Pompei P., Ales K., Mackenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5): 373–83. https://doi.org/10.1016/0021-9681(87)90171-8 PMID: 3558716

12. Morley J., Malmstrom T., Miller D. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012; 16(7): 601–8. https://doi.org/10.1007/s12603-012-0084-2 PMID: 22836700

13. Tsoi K.K., Chan J.Y., Hirai H.W., et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015; 175(9): 1450–8. https://doi.org/10.1001/jamainternmed.2015.2152 PMID: 26052687

14. Андрюшенко А.В., Дробижев М.Ю., Добровольский А.В. Сравнительная оценка шкал CES-D, BDI и HADS(d) в диагностике депрессий в общемедицинской практике. Журнал неврологии и психиатрии. 2003; 5: 11–8.

15. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2016; 253: 281–344. https://doi.org/10.1016/j.atherosclerosis.2016.08.018

16. Morisky D.E, Green L.W, Levine D.M. Concurrent and predictive validity of self-reported measure of medical adherence. Med Care. 1986; 24: 67–73. https://doi.org/10.1097/00005650-198601000-00007

17. Conn V.S., Hafdahl A.R., Cooper P.S., et al. Interventions to Improve Medication Adherence Among Older Adults: Meta-Analysis of Adherence Outcomes Among Randomized Controlled Trials. Gerontologist. 2009; 49(4): 447–62. https://doi.org/10.1093/geront/gnp037 PMID: 19460887

18. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П. и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012; 11(4): 70–8. https://doi.org/10.15829/1728-8800-2012-4-70-78

19. Reiner Ž., De Backer G., Fras Z., et al. On behalf of the EUROASPIRE Investigators Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries e Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016; 246: 243–50. https://doi.org/10.1016/j.atherosclerosis.2016.01.018 PMID: 26812002

20. Шальнова С.А., Деев А.Д., Метельская В.А. и др. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2016; 15(4): 29–37. https://doi.org/10.15829/1728-8800-2016-4-29-37

21. Ахмеджанов Н. М., Небиеридзе Д. В., Сафарян А. С. и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I. Рациональная фармакотерапия в кардиологии. 2015; 11(3): 253–60. https://doi.org/10.20996/1819-6446-2015-11-3253-260

22. Ofori-Asenso R., Jakhu A., Curtis A.J., et al. A systematic review and meta-analysis of the factors sssociated with nonadherence and discontinuation of statins among people aged ≥65 Years. J Gerontol A Biol Sci Med Sci. 2018 May 9; 73(6): 798–805. https://doi.org/10.1093/gerona/glx256 PMID: 29360935

23. Yu G., Zhang Y., Wang Y., et al. Factors that contribute to poor adherence to statin therapy in coronary heart disease patients from Chongqing and measures to improve their therapeutic outcomes. Genes Dis. 2018; 5(4): 335–41. https://doi.org/10.1016/j.gendis.2018.01.001 PMID: 30591935

24. Mann D.M., Allegrante J.P., Natarajan S., et al. Predictors of Adherence to Statins for Primary Prevention. Cardiovasc Drugs Ther. 2007; 21: 311–6. https://doi.org/10.1007/s10557-007-6040-4 PMID: 17665294

25. Barnett K., Mercer S.W., Norbury M., et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380(9836): 37–43. https://doi.org/10.1016/S0140-6736(12)60240-2

26. Lavikainen P., Helin-Salmivaara A., Eerola M., et al. Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence. BMJ Open. 2016; 6(6): e011306. https://doi.org/10.1136/bmjopen-2016-011306 PMID: 27259530

27. Hope H.F., Binkley G.M., Fenton S., et al. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE. 2019; 14(1): e0201196. https://doi.org/10.1371/journal.pone.0201196 PMID: 30653535

28. Mohammed S., Arabi A., El-Menyar A., et al. Impact of polypharmacy on adherence to evidence-based medication in patients who underwent percutaneous coronary Intervention. Curr Vasc pharmacol. 2016; 14(4): 388–93. https://doi.org/10.2174/1570161113666151030105805 PMID: 26517700

29. Collard R.M., Boter H., Schoevers R.A., Oude Voshaar R.C. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012; 60(8): 1487–92. https://doi.org/10.1111/j.1532-5415.2012.04054.x PMID: 22881367

30. Kirkpatrick A.C., Vincent A.S., Guthery L., Prodan C.I. Cognitive impairment is associated with medication nonadherence in asymptomatic carotid stenosis. Am J Med. 2014; 127(12): 1243–46. https://doi.org/10.1016/j.amjmed.2014.08.010 PMID: 25168078

31. Журавская Н.Ю., Кутишенко Н.П., Марцевич С.Ю. и др. Изучение приверженности врачебным рекомендациям у пациентов, перенесших мозговой инсульт. Роль тревоги и депрессии. (Результаты регистра ЛИС-2). Кардиоваскулярная терапия и профилактика. 2015; 14(2): 46–51. https://doi.org/10.15829/1728-8800-2015-2-46-51